JP2017530984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530984A5 JP2017530984A5 JP2017518802A JP2017518802A JP2017530984A5 JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5 JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- composition
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*(C)NC(C1CC1)=O Chemical compound C*(C)NC(C1CC1)=O 0.000 description 9
- SMNAXTKCDCNAQG-YCHJVJMSSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N SMNAXTKCDCNAQG-YCHJVJMSSA-N 0.000 description 1
- IDHXNQZUWRNLSI-OAJVMADHSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N IDHXNQZUWRNLSI-OAJVMADHSA-N 0.000 description 1
- WWKQLKZHPMHBSM-UHFFFAOYSA-N CC(C)[n]1nc(cccc2)c2c1 Chemical compound CC(C)[n]1nc(cccc2)c2c1 WWKQLKZHPMHBSM-UHFFFAOYSA-N 0.000 description 1
- MPBYIDFVBMROTH-UHFFFAOYSA-N CC(C)[n]1ncc(c(F)c2)c1cc2Br Chemical compound CC(C)[n]1ncc(c(F)c2)c1cc2Br MPBYIDFVBMROTH-UHFFFAOYSA-N 0.000 description 1
- QYWHLIHVMLNPCM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 QYWHLIHVMLNPCM-UHFFFAOYSA-N 0.000 description 1
- ISYYMZGUNVIDIJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 ISYYMZGUNVIDIJ-UHFFFAOYSA-N 0.000 description 1
- PSJNUJQXRJBICQ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 PSJNUJQXRJBICQ-UHFFFAOYSA-N 0.000 description 1
- JLUCSGYYDOSGIT-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 JLUCSGYYDOSGIT-UHFFFAOYSA-N 0.000 description 1
- ADOPLAZEYVDBNR-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 ADOPLAZEYVDBNR-UHFFFAOYSA-N 0.000 description 1
- NYBLIBCAYAWPIF-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 NYBLIBCAYAWPIF-UHFFFAOYSA-N 0.000 description 1
- UWUKMXRNRWPXRV-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 UWUKMXRNRWPXRV-UHFFFAOYSA-N 0.000 description 1
- ZMMWAYLSGNDHBJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 ZMMWAYLSGNDHBJ-UHFFFAOYSA-N 0.000 description 1
- DKUQJFPELDXTEG-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 DKUQJFPELDXTEG-UHFFFAOYSA-N 0.000 description 1
- AMLCZZBEFOGSRO-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 AMLCZZBEFOGSRO-UHFFFAOYSA-N 0.000 description 1
- FHHZGVYBDCHFED-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 FHHZGVYBDCHFED-UHFFFAOYSA-N 0.000 description 1
- ZDEOCJBDKFWTIB-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 ZDEOCJBDKFWTIB-UHFFFAOYSA-N 0.000 description 1
- GYTIXMGHYWYHPM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 GYTIXMGHYWYHPM-UHFFFAOYSA-N 0.000 description 1
- JUGFUMWWAFDCJZ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 JUGFUMWWAFDCJZ-UHFFFAOYSA-N 0.000 description 1
- CKMKMCGQKLICGJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 CKMKMCGQKLICGJ-UHFFFAOYSA-N 0.000 description 1
- JDIJRRHONXUUMY-BIAFCPFJSA-N CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 Chemical compound CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 JDIJRRHONXUUMY-BIAFCPFJSA-N 0.000 description 1
- CJNWKQKFHSMHHI-UHFFFAOYSA-N CC(C1CNC1)=O Chemical compound CC(C1CNC1)=O CJNWKQKFHSMHHI-UHFFFAOYSA-N 0.000 description 1
- NGGWJGZAKJHKSZ-UHFFFAOYSA-N CC1C=CC(C(NC)=O)=CC1 Chemical compound CC1C=CC(C(NC)=O)=CC1 NGGWJGZAKJHKSZ-UHFFFAOYSA-N 0.000 description 1
- ZHJJLMNCPIHBRM-UHFFFAOYSA-N CC1C=Cc2n[n](C)cc2C1F Chemical compound CC1C=Cc2n[n](C)cc2C1F ZHJJLMNCPIHBRM-UHFFFAOYSA-N 0.000 description 1
- FJXRIACJPBCMCU-JOAIZHEFSA-O CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 Chemical compound CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 FJXRIACJPBCMCU-JOAIZHEFSA-O 0.000 description 1
- GQJXSYYQPWIJOU-ZNDRMEFZSA-N CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 Chemical compound CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 GQJXSYYQPWIJOU-ZNDRMEFZSA-N 0.000 description 1
- YCDDKKGCWDMJKY-SSDOTTSWSA-N CNC(C(C1)=CC=C[C@H]1I)=O Chemical compound CNC(C(C1)=CC=C[C@H]1I)=O YCDDKKGCWDMJKY-SSDOTTSWSA-N 0.000 description 1
- TZAYNGPUOOUEAP-UHFFFAOYSA-N C[n]1nc(C(F)(F)F)c(Br)c1 Chemical compound C[n]1nc(C(F)(F)F)c(Br)c1 TZAYNGPUOOUEAP-UHFFFAOYSA-N 0.000 description 1
- WQYAKZVLTOWKQB-UHFFFAOYSA-N C[n]1ncc(cc2)c1nc2Cl Chemical compound C[n]1ncc(cc2)c1nc2Cl WQYAKZVLTOWKQB-UHFFFAOYSA-N 0.000 description 1
- CSUGQXMRKOKBFI-UHFFFAOYSA-N C[n]1ncc2ccccc12 Chemical compound C[n]1ncc2ccccc12 CSUGQXMRKOKBFI-UHFFFAOYSA-N 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N O=Cc1ccccc1 Chemical compound O=Cc1ccccc1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014088309 | 2014-10-10 | ||
| CNPCT/CN2014/088309 | 2014-10-10 | ||
| PCT/US2015/054949 WO2016057924A1 (en) | 2014-10-10 | 2015-10-09 | Pyrrolidine amide compounds as histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530984A JP2017530984A (ja) | 2017-10-19 |
| JP2017530984A5 true JP2017530984A5 (enExample) | 2018-11-22 |
| JP6783230B2 JP6783230B2 (ja) | 2020-11-11 |
Family
ID=54337935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518802A Expired - Fee Related JP6783230B2 (ja) | 2014-10-10 | 2015-10-09 | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10022354B2 (enExample) |
| EP (1) | EP3204379B1 (enExample) |
| JP (1) | JP6783230B2 (enExample) |
| CN (1) | CN107912040B (enExample) |
| WO (1) | WO2016057924A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| KR20190063745A (ko) * | 2017-11-30 | 2019-06-10 | (주)인핸스드바이오 | p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7017704B2 (ja) * | 2018-09-10 | 2022-02-09 | 株式会社島津製作所 | 生体膜ホスホイノシタイドの分離方法 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| CN109852662B (zh) * | 2018-12-25 | 2021-02-19 | 华南农业大学 | 组蛋白甲基化H3K4me3在猪卵巢颗粒细胞中的应用 |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| US20220289751A1 (en) * | 2019-07-17 | 2022-09-15 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| US12565504B2 (en) * | 2019-10-29 | 2026-03-03 | Biogen Ma Inc. | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021154966A1 (en) * | 2020-01-29 | 2021-08-05 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| CN111138289B (zh) * | 2020-02-27 | 2022-08-30 | 奥锐特药业(天津)有限公司 | 一种化合物及使用该化合物合成5-乙酰基-1h-吡唑-3-羧酸的工艺 |
| US12552806B2 (en) | 2020-03-20 | 2026-02-17 | University Of Southern California | Androgen receptor regulation by small molecule enantiomers |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4146645B1 (en) * | 2020-05-07 | 2025-06-25 | ONO Pharmaceutical Co., Ltd. | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
| ES3054072T3 (en) | 2020-08-07 | 2026-01-29 | Gilead Sciences Inc | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022087422A1 (en) * | 2020-10-22 | 2022-04-28 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| TWI907744B (zh) * | 2021-11-05 | 2025-12-11 | 日商小野藥品工業股份有限公司 | 包含具有kdm5抑制活性之化合物之醫藥組合物 |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| CN116284202B (zh) * | 2023-03-28 | 2024-07-02 | 华侨大学 | 白桦脂酸的PROTACs化合物及其制备方法和应用 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| PL2366699T3 (pl) * | 2008-10-02 | 2013-12-31 | Asahi Kasei Pharma Corp | 8-podstawiona pochodna izochinoliny i jej zastosowanie |
| US8513244B2 (en) * | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| BR112014026176A2 (pt) * | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | dipiridilaminas substituídas e usos das mesmas |
| MX2015006191A (es) * | 2012-11-16 | 2015-08-10 | Merck Sharp & Dohme | Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana. |
| US9738637B2 (en) * | 2013-03-12 | 2017-08-22 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| RU2015143517A (ru) * | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
-
2015
- 2015-10-09 WO PCT/US2015/054949 patent/WO2016057924A1/en not_active Ceased
- 2015-10-09 JP JP2017518802A patent/JP6783230B2/ja not_active Expired - Fee Related
- 2015-10-09 CN CN201580066844.9A patent/CN107912040B/zh not_active Expired - Fee Related
- 2015-10-09 EP EP15784257.6A patent/EP3204379B1/en active Active
-
2017
- 2017-04-07 US US15/482,584 patent/US10022354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505169A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2017528524A5 (enExample) | ||
| JP2016529312A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2018525441A5 (enExample) | ||
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2016516020A5 (enExample) | ||
| JP2016539134A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2017101088A (ja) | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法 | |
| JP2021502345A (ja) | 抗がん剤 | |
| JP2009504764A5 (enExample) | ||
| JP2015500209A5 (enExample) | ||
| JP2015518004A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2016525097A5 (enExample) |